In 2020, a company called Genomic Prediction started offering genomic scores for diabetes, skin cancer, high blood pressure, elevated cholesterol, intellectual disability, and “idiopathic short stature.” They’ve stopped advertising the last two “because it’s too controversial.” Not, mind you, because the effects are minor and the science is unreliable. The theoretical maximum polygenic score for height would make a difference of 2.5 inches, and that theoretical maximum has not been seen yet, even in studies of Europeans. Polygenic scores for most other traits lag far behind. (And that’s just one company; another called Herasight has since picked up the slack and claims to offer embryo selection based on intelligence.)
→ Continue reading at Ars Technica